WallStSmart
KROS

Keros Therapeutics Inc

NASDAQ: KROS · HEALTHCARE · BIOTECHNOLOGY

$11.12
+0.18% today

Updated 2026-04-30

Market cap
$228.75M
P/E ratio
5.03
P/S ratio
0.94x
EPS (TTM)
$2.30
Dividend yield
52W range
$10 – $23
Volume
0.4M

Keros Therapeutics Inc (KROS) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20182019202020212022202320242025
Revenue$10.00M$10.00M$2.50M$20.10M$20.00M$151000.00$3.55M$244.06M
Revenue growth (YoY)+0.0%-75.0%+704.0%-0.5%-99.2%+2251.0%+6775.0%
Cost of revenue$10.11M$17.35M$605000.00$898000.00$1.61M$815000.00$1.23M$1.51M
Gross profit$-111000.00$-7.35M$-605000.00$20.10M$-1.61M$151000.00$3.55M$242.55M
Gross margin-1.1%-73.5%-24.2%100.0%-8.1%100.0%100.0%99.4%
R&D$10.11M$17.38M$33.86M$55.14M$87.27M$135.26M$173.63M$129.64M
SG&A$1.58M$3.18M$12.80M$21.33M$27.52M$34.83M$40.75M$46.85M
Operating income$-1.69M$-10.56M$-46.66M$-56.37M$-114.79M$-169.94M$-210.83M$70.62M
Operating margin-16.9%-105.6%-1866.3%-280.5%-573.9%-112543.7%-5939.0%28.9%
EBITDA$-774000.00$-11.89M$-44.92M$-56.35M$-104.00M$-152.18M$-185.82M$72.13M
EBITDA margin-7.7%-118.9%-1796.9%-280.4%-520.0%-100779.5%-5234.5%29.6%
EBIT$-1.08M$-12.33M$-45.53M$-56.73M$-104.68M$-152.99M$-187.05M$70.62M
Interest expense$6000.00$8000.00$6000.00$4000.00$1000.00$0.00$0.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-1.33M$-12.34M$-45.36M$-58.74M$-104.68M$-152.99M$-187.35M$87.01M
Net income growth (YoY)-824.6%-267.5%-29.5%-78.2%-46.2%-22.5%+146.4%
Profit margin-13.4%-123.4%-1814.4%-292.3%-523.4%-101319.2%-5277.5%35.7%